Investment Memorandum: MiniMed Group, Inc. (NASDAQ: MMED)

1. Executive Investment Thesis and Strategic Positioning

The impending initial public offering (IPO) of MiniMed Group, Inc. (MMED) marks a definitive structural evolution in the diabetes technology sector. By carving out its Diabetes Operating Unit, Medtronic plc is transitioning a legacy pioneer into a focused, pure-play entity. This separation is designed to unlock the intrinsic value of a business that has historically been obscured within a diversified conglomerate. For institutional investors, MMED provides concentrated exposure to the $18 billion intensive insulin management market, offering a unique combination of established global scale and a newly agile innovation roadmap.

The core investment thesis rests on a compelling acceleration story. The Bull Case is supported by a clear trend of revenue growth—bolstered by preliminary Q3 FY2026 results showing 14.8% reported growth—and a pipeline shift toward the tubeless "patch-pump" category that addresses a long-standing competitive gap. Conversely, the Bear Case centers on the technical and governance risks of the "Medtronic Overhang." With Medtronic retaining 90.03% of the voting power, MMED enters the market as a controlled company, facing immediate competitive pressure from agile incumbents and potential margin drag from recent manufacturing inefficiencies.

This initial valuation represents a significant discount to pure-play peers, setting the stage for a detailed examination of whether MiniMed's foundational assets and standalone focus can drive a valuation re-rating.

2. Business Overview: The Evolution of a Pure-Play Diabetes Leader

MiniMed's legacy is a primary pillar of its investment profile. Tracing its roots back to 1983, the company has commercialized the first wearable pumps and pioneered the hybrid closed-loop category. This history has allowed MiniMed to secure a "data moat" of over 430 million data points from more than 640,000 pump users worldwide. For an institutional investor, this is not merely a historical footnote; it is the critical clinical substrate required to train the next generation of Automated Insulin Delivery (AID) algorithms, a barrier to entry that newer, smaller competitors cannot easily replicate.

The transition from a Medtronic Operating Unit to a standalone entity is intended to "sharpen the focus" of the organization. As a pure-play, MMED can escape the capital allocation constraints of a larger parent, prioritizing R&D agility and responsiveness to patient preference—an area where it has previously lagged. This operational independence is vital for a company that already possesses the infrastructure to dominate on a global scale.

This global scale provides the necessary distribution backbone for its technology, but its ultimate success will depend on the clinical superiority and user experience of its integrated platform.

3. Product Ecosystem and Innovation Pipeline Analysis

MiniMed's competitive edge is defined by its "Full-Ecosystem" strategy. While competitors often provide fragmented solutions, MiniMed integrates the pump, Continuous Glucose Monitor (CGM), and proprietary SmartGuard software into a single, seamless app-based environment (CareLink). This vertical integration is a powerful driver of patient adherence and clinical outcomes, as it eliminates the technical friction inherent in managing multi-vendor hardware.

The "So What?" for the innovation pipeline is the upcoming transition from tubed to tubeless delivery. Historically, MiniMed's reliance on tubed pumps was a strategic vulnerability. The 2026–2027 pipeline, specifically the transition from the MiniMed Flex (a screenless tubed pump) to the MiniMed Fit (a tubeless patch pump), directly challenges the dominance of Insulet's Omnipod. Furthermore, the 430 million data points mentioned previously are the primary fuel for the "Vivera Algorithm," a next-gen fully closed-loop system currently in pivotal studies.

4. Financial Performance and Operational Metrics

MiniMed's financial profile reveals a business in a state of deliberate transition. The company has demonstrated a clear acceleration in revenue growth: moving from 10.0% in FY2025 to 13.1% in H1 FY2026, and reaching 14.8% in preliminary Q3 FY2026 results. However, this growth is currently paired with unprofitability, primarily due to a 165 million litigation charge and a 118 million Simplera manufacturing charge in Q1 2026. For investors, this manufacturing charge is a tactical concern, as it suggests early friction in scaling the new sensor technology which could pressure margins through the transition.

The most critical leading indicator is the CGM attachment rate, which has expanded from 58% to approximately 67%. This is vital because 83% of MiniMed's revenue is recurring (consumables, sensors, and software). As attachment rates rise, the Customer Lifetime Value (LTV) increases, providing a high-margin floor for future profitability once one-time separation and litigation costs are cleared.

5. Valuation Analysis and Peer Benchmarking

At an implied multiple of 2.6x to 2.9x LTM revenue, MiniMed enters the public market at a substantial discount. Pure-play peers such as Dexcom and Insulet often trade at 5x to 10x sales. This "conglomerate discount" is largely a vestige of its time under Medtronic. We believe there is significant valuation re-rating potential to the 5–7x sales range if the company successfully executes the launches of the "Fit" and "Flex" platforms, proving it can reclaim domestic market share.

MiniMed's ability to offer a single point of contact and a unified software experience is a differentiator that simplifies clinical adoption for healthcare providers and insurers alike.

6. Risk Assessment: Governance and Market Volatility

The primary risk for MMED is its "Controlled Company" status. With Medtronic holding 90.03% of the voting power, minority shareholders have limited influence over strategic direction or board appointments. This structure serves as a barrier to potential activist intervention. Furthermore, the "Medtronic Overhang" is a technical risk; the planned full split-off by end-2026 will eventually flood the market with shares, potentially creating a ceiling on the stock price in the near term regardless of fundamental performance.

7. Final Institutional Recommendation

The MiniMed IPO offers a compelling entry point into the "diabetes megatrend" at a reasonable valuation. The company is successfully pivoting from a legacy hardware manufacturer to a software-centric, integrated health technology leader. While the Medtronic overhang and manufacturing charges present near-term headwinds, the underlying acceleration to 14.8% growth and the robust data moat suggest significant long-term upside.